GlassScriptPhysician profile
Jayasankar K Reddy
NPI 1174562276
$27,778.16
in general payments reported to CMS, 2019-2025
25 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $3,884 · 2021: $4,140 · 2022: $8,389 · 2023: $9,904 · 2024: $493 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,781 · Consulting Fee: $3,450 · Food and Beverage: $2,004 · Honoraria: $1,563 · Travel and Lodging: $369 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,781.25 |
| Consulting Fee | $3,450.00 |
| Food and Beverage | $2,003.69 |
| Honoraria | $1,562.50 |
| Travel and Lodging | $368.58 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $19,682.58 | 2019-2023 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $3,095.18 | 2023-2025 | Korsuva, Velphoro, Velphoro |
| Vifor Fresenius Medical Care Renal Pharma LTD. | $2,618.58 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $762.93 | 2021-2025 | |
| Amgen INC. | $239.63 | 2021-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $215.39 | 2019-2024 | Farxiga |
| Opko Pharmaceuticals, LLC | $174.17 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $162.64 | 2025 | Filspari |
| Ani Pharmaceuticals, INC. | $119.93 | 2024-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $112.92 | 2021-2023 | Jynarque |
| Horizon Therapeutics Plc | $85.60 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $76.91 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.97 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $65.73 | 2020 | |
| Mallinckrodt Hospital Products INC. | $62.48 | 2022-2023 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $39.08 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $38.35 | 2020-2021 | |
| Glaxosmithkline, LLC. | $23.93 | 2021 | |
| Calliditas Therapeutics US INC. | $21.69 | 2022 | |
| Scpharmaceuticals INC. | $19.47 | 2025 | |
| Angiodynamics, INC. | $18.94 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.13 | 2021 | |
| Baxter Healthcare | $17.76 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayasankar Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.